Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase IIIb, Randomised Parallel Group Study to Assess the Efficacy and Safety of Switching HIV-1 Infected Patients Successfully Treated With a Nevirapine IR Based Regiment to Nevirapine XR 400 mg QD or Remaining on Nevirapine IR 200 mg BID Based Program

NCT00819052 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00819052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00819052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase IIIb, Randomised Parallel Group Study to Assess the Efficacy and Safety of Switching HIV-1 Infected Patients Successfully Treated With a Nevirapine IR Based Regiment to Nevirapine XR 400 mg QD or Remaining on Nevirapine IR 200 mg BID Based Program
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2008
Completion date
January 31, 2012
Enrollment
445 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections